Objective-To report on the short-term and long-term results of patients who underwent a third coronary balloon angioplasty for a second restenosis and to identify the correlates of a third clinical restenosis. Design-A retrospective analysis of clinical, angiographic, and procedure related variables of a consecutive series of patients. angioplasty procedure as the only independent predictor of a third clinical restenosis (P = 0-004). Conclusions-A third coronary angioplasty for a second restenosis can be performed safely and effectively and should be considered as an integral part of the overall coronary angioplasty revascularisation strategy. The incidence of a third clinical restenosis remains high, however, and is correlated with the interval between the previous angoplasty procedures. (Br Heart J 1995;73:327-333) 
went a third coronary balloon angioplasty of a single coronary artery segment at which restenosis had occurred after two previous angioplasty procedures between 1986 and 1992. Results-Procedure success was achieved in 56 patients (90%). Complications included one myocardial infarction (2%) and one emergency coronary artery bypass surgery (2%). Complete follow up data were available (median (range) 48 (12-94) months). During the follow up period, four patients (6%) died, two (3%) had a non-fatal myocardial infarction, and five (8%) underwent elective coronary artery bypass surgery. Nine patients (14%) underwent a fourth angioplasty for a third clinical restenosis, and three (5%) had a fourth angioplasty procedure for new coronary lesions. The cumulative probability of survival for all 62 patients was 97% and 95% at 1 and 5 years, respectively. The 1 and 5 year freedom from death, infarction, bypass surgery, and repeat angioplasty was 82% and 66-6%, respectively. At census, of the 58 survivors, 31 (53%) were asymptomatic and only eight (14%) complained of angina grade III or IV (P < 0.001). A third clinical restenosis occurred in 22 (39%) of the 56 patients who had initially successful procedures. Multiple stepwise logistic regression analysis identified the interval between the second and third angioplasty procedure as the only independent predictor of a third clinical restenosis (P = 0-004). Conclusions-A third coronary angioplasty for a second restenosis can be performed safely and effectively and should be considered as an integral part of the overall coronary angioplasty revascularisation strategy. The incidence of a third clinical restenosis remains high, however, and is correlated with the interval between the previous angoplasty procedures. (Br Heart J 1995; 73:327-333) Keywords: recurrent restenosis; revascularisation; balloon angioplasty Despite continuing improvement in primary success rate restenosis remains the major limitation of percutaneous transluminal coronary angioplasty. The reported incidence ranges from 16% to 47% depending on the population studied. [1] [2] [3] The efficacy of a second coronary angioplasty for a first restenosis has been well documented, and earlier studies have reported higher acute success and lower complication rates than those usually reported for a first angioplasty.4-6 Hence, treatment of restenosis with a repeat angioplasty has become routine clinical practice, and is currently accepted as an integral part of the overall coronary angioplasty revascularisation strategy. [7] [8] [9] Although a second recurrence is no more likely than a first, restenosis after a second angioplasty is nevertheless associated with an incidence ranging from 26% to 34% in previously reported series.' 1"2 Patients with restenosis after a second angioplasty will become an increasing clinical problem as growth in the volume of angioplasties continues. Although a third angioplasty for a second restenosis has been shown to be technically feasible and safe, information about late outcome is limited."3-'5 Whether these patients should be subjected to a third angioplasty, or whether coronary artery bypass grafting is the preferred mode of revascularisation at this stage remains unanswered. In addition, the ability to identify those patients at higher risk of a subsequent restenosis will have important implications in planning and optimising individual therapeutic strategy.
To resolve some of these issues, this study reports on the acute success and long-term follow up of patients who underwent a third coronary balloon angioplasty for a second restenosis. The correlates of clinical restenosis after a third angioplasty were also examined.
transluminal coronary balloon angioplasty of a single coronary arterial segment at which restenosis had occurred after two previous angioplasties. Patients who had their third angioplasty within two weeks of the preceding procedure were not included in the study to exclude patients who had repeat dilatation because of periprocedural complication. The median (range) time interval between the second and the third angioplasty was 6 (1-22) months.
The mean (SD) (range) age was 53 (9) (31-72) years and 52 (84%) were male ( femoral approach was used in all cases. All patients received oral aspirin and most patients were sedated with intravenous diazepam. A total of 10 000 units of intraarterial heparin were administered at the start of the procedure. Additional boluses were given to maintain an activated clotting time of >300 s. Adaptations were made to accommodate technical advances such as the development of low profile, steerable balloon catheters throughout the study period. Balloon size was selected to approximate the diameter of the adjacent normal segment of the coronary artery. Intravenous infusions of heparin and nitrate were continued for 24 h after angioplasty.
A total of 74 vessels and 85 stenoses were attempted during the same procedure. Of the 62 coronary artery segments dilated for the third time for a second restenosis, 33 (53%) were located in the left anterior descending artery and its diagonal branches, nine (15%) in the circumflex artery and its obtuse marginal branches, 15 (24%) in the right coronary artery, and five (8%) in saphenous vein grafts. Three procedures were undertaken for totally occluded vessels. Of the remaining 23 stenoses dilated in those patients who underwent multilesion angioplasty, 18 were dilated for the first time and five for the second time.
METHODS
The baseline clinical, angiographic, and procedural data of the 62 patients were assessed. Angiographic details were assessed by two independent observers. The opinion of a third experienced cardiologist was obtained if there was disagreement. Quantitative measurements were made using hand held callipers on projected angiographic film using the image of the guiding catheter for magnification scaling. A protractor was used for measuring lesion angulation. Lesion complexity was classified as type A, Bi, B2, C1, or C2 using the morphological characteristics initially described by the American Heart Association/American College of Cardiology Task Force as modified by Ellis et Complete follow up data obtained at routine clinic visits, from the referring physicians, and by telephone interview with the patients were available for the 62 patients. All patients were eligible for at least six months' follow up after the procedure. Information on vital status, angina status, and the occurrence of new cardiac events (defined as myocardial infarction, coronary artery bypass grafting, or repeat coronary angioplasty) was obtained.
At our centre patients are followed closely by functional testing for the development of symptoms or signs of myocardial ischaemia after angioplasty. The indication for follow up coronary angiography was strictly clinical: recurrence of angina pectoris, or a positive symptom limited treadmill exercise test performed routinely during outpatient visits.
The patient related variables analysed as possible determinants of restenosis included age, sex, angina grade, presentation with unstable angina, extent of coronary artery disease, left ventricular function, and the time interval between second and third angioplasty. Other variables considered were a history of smoking, hypertension, diabetes mellitus, hypercholesterolaemia, previous myocardial infarction, previous coronary artery bypass surgery, and presence of family history. The lesion related variables analysed as possible determinants of restenosis included lesion length, eccentricity, angulation, contour, calcification, and location (ostial, proximal, mid, or distal). Other variables considered were vessel diameter, vessel location, pre-angioplasty percentage stenosis, post-angioplasty percentage stenosis, presence of distal ectasia, presence of thrombus, and presence of post-angioplasty dissection. The procedure related variables analysed as possible determinants of restenosis included the number of inflations, maximum inflation pressure, maximum inflation duration, total inflation duration, and balloon to artery ratio.
DEFINITIONS
Procedural success was defined as < 50% residual diameter stenosis at the dilated sites without a major complication (invariably the result of an abrupt occlusion of the vessel being dilated), defined as death, myocardial infarction, or emergency coronary artery bypass grafting, at any time during hospitalisation. Success was judged in patients who underwent multivessel or multilesion coronary angioplasty according to the outcome of the coronary artery segment dilated for the third time for a second restenosis. If a significant inhospital complication occurred as a result of dilating another lesion despite angiographic success for the coronary artery segment which had recurrent restenosis, however, the procedure was judged to be a failure. Angiographic restenosis was defined as a recurrence of a >50% diameter stenosis at a previously successfully dilated site. Clinical restenosis was defined as the recurrence of anginal symptoms or evidence of reversible ischaemia associated with angiographic evidence of restenosis. Patients who had a cardiac death or a non-fatal myocardial infarction during the follow up period were also considered as having had a clinical restenosis. 
LONG-TERM RESULTS
Complete follow up data were available for the 62 patients on or after the census date. The median (range) duration of follow up was 48 (12-94) months. During the follow up period, four patients (6%) died, two (3%) suffered a non-fatal myocardial infarction, and five (8%) underwent elective coronary artery bypass grafting. Nine patients (14%) underwent a fourth angioplasty for a third restenosis and three (5%) had a fourth angioplasty for new coronary lesions. Overall, a second revascularisation procedure was necessary in 17 patients (27%). The four late deaths included two cardiac deaths (one sudden death and one fatal myocardial infarction), one from elective coronary artery bypass grafting for restenosis, and one from repeat angioplasty for new coronary lesions.
The cumulative probability of survival for all 62 patients was 96-8% (SE 2 2) at 1 year and 95 0% (SE 2 8) at 5 years after percutaneous transluminal coronary angioplasty (PTCA) (table 2). Both the 1 and 5 year cumulative survival rates for patients with initially successful angioplasties were 96&2% (SE 2-7). Table 2 gives total and event free survival rates at 1 and 5 years after PTCA for all patients, and those with initially successful procedures, while figure 1 shows the total and event free survival rates for 0-5 years after PTCA for all patients and figure 2 survival 
Discussion
The long-term efficacy of PTCA has been hampered by the problem of restenosis. 1-3 The management of patients with recurrent restenosis has become a common but difficult clinical problem with the expansion of the indication for coronary angioplasty. Because its efficacy has been well documented, performance of a second angioplasty after the first restenosis has become routine clinical practice.4-10 Whether further restenosis should be treated with angioplasty or coronary artery bypass surgery is less certain. This study aimed to examine the efficacy of a third angioplasty when two previous procedures were followed by restenosis.
SHORT-TERM RESULTS
The success and complication rates in this study were encouraging, and did not differ from the rates usually reported for first angioplasties.0-" Other studies of coronary angioplasty for a second restenosis have reported clinical success rates of 92-97%, consistent with the 90% in our study."' 1415 Procedural mortality ranging from 0 to 2-7%, myocardial infarction rates ranging from 0 to 2-8%, and emergency bypass surgery rates ranging from 0 to 4 9% have also been reported (table 3) . In the present study, the corresponding mortality, myocardial infarction, and emergency bypass surgery rates were 0%, 1 6% and 1 6%, respectively. The favourable results may reflect the highly selected population in these studies, in that these patients have already had two previous successful procedures at the target site, or it may be the result of differences in the physical properties of restenotic lesions compared with those of primary lesions.'4
LONG-TERM RESULTS
Although angioplasty for recurrent restenosis is technically feasible, the procedure must be associated with short-and long-term symptomatic improvement to be judged as clinically successful. be accounted for by differences in the rate of angiographic follow up, especially low in patients who were asymptomatic, and in the definition of restenosis. Although multiple variables have been associated with an increased first restenosis rate, the only variable found to be independently predictive of a third clinical restenosis in the present study was the time interval between the second and the third procedure. The finding that a short time interval between previous restenoses is predictive of future restenoses has been consistently reported by other investigators, although the reason remains unclear. Teirstein et al'3 have shown that the mean time interval between the second and the third angioplasty procedure was 4 9 months in patients who subsequently developed a third restenosis and 6-4 months in those who did not. Dimas et all5 have reported that the mean time interval between the first and the second angioplasty was 3-6 months in patients who subsequently developed a second restenosis and 6-1 months in those who did not. In the study by Quigley et al,8 the corresponding mean time interval between the first and the second angioplasty was 4'5 months and 7 1 months. Black et al 12 have shown that a time interval of <5 months between the first and the second angioplasty is predictive of a second restenosis. Bauters et al 14 have shown that a time interval of < 3 months between the second and the third angioplasty is associated with recurrent restenosis. The disparate time intervals between the studies probably reflect differences in the delay between symptom recurrence as a result of restenosis and admission of patients for a repeat angioplasty. One possible explanation is that the short time interval between angioplasty reflects the increased tendency of the patient to develop intense smooth muscle cell proliferation. Another possibility is that the short time interval between successive angioplasties enhances the degree of neointimal hyperplasia in response to the injury caused by the balloon inflation, resulting in the development of early restenosis.24
LIMITATIONS
Although the study population consisted of a consecutive group that underwent coronary angioplasty for a second restenosis, the study is a retrospective analysis of data and is subject to all the limitations inherent in such a study.
The rate of repeat coronary angiography was low (46%) as the procedure was performed only in patients who were symptomatic or had evidence of reversible ischaemia documented using non-invasive investigation. Therefore the exact angiographic restenosis rate cannot be determined.
Conclusions
The decision in choosing the mode of revascularisation in patients with recurrent restenosis depends on many factors, including the feasibility and safety of the procedure, the long-term efficacy, and patient or clinician preference. Our study has shown that a third coronary angioplasty for a second restenosis can be performed safely and effectively in selected patients, and provides good symptomatic relief and favourable long-term outcome. This suggests that multiple repeated angioplasty for recurrent restenosis can be accepted as an integral part of the overall coronary angioplasty revascularisation strategy and provides an attractive alternative to coronary bypass surgery in this group of patients. Although the incidence of restenosis remains high, the majority are relieved of symptoms by subsequent angioplasties. A high risk of subsequent clinical restenosis can be predicted from the time interval between the previous procedures, hence allowing an alternative mode of revascularisation to be considered in these patients.
New revascularisation technologies, such as stents and atherectomy, are currently under investigation. Randomised trials comparing directional atherectomy with balloon angioplasty have not shown any conclusive reduction in the rate of restenosis, or improvement in clinical outcome.2526 Results from randomised studies of de novo stent implantation using the Palmaz-Schatz device have demonstrated a reduction in restenosis rates compared with those of balloon angioplasty, but the risks associated with stenting are substantial.2728 The need for intensive anticoagulant treatment requires prolonged hospitalisation, and results in bleeding problems, manifesting as a need for transfusion or major peripheral vascular complications. Furthermore, stent implantation is expensive, and the long-term results are not known. Further results should be awaited before drawing final conclusions on the merits of primary stenting. Until then, this study provides useful information in helping clinicians and patients to decide the most appropriate therapeutic course after recurrent restenosis has occurred.
